Alector, Inc. (ALEC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alector, Inc. (ALEC) Healthcare & Pipeline Overview

Alector, Inc. pioneers immuno-neurology, developing novel therapies targeting the brain's immune system to combat neurodegenerative diseases like Alzheimer's and Parkinson's. Their clinical-stage pipeline, featuring monoclonal antibodies and strategic collaborations with companies like GlaxoSmithKline, positions them in the competitive biotechnology landscape.

What Is the Investment Thesis for ALEC?

Alector's investment thesis hinges on the potential of its immuno-neurology approach to address significant unmet needs in neurodegenerative diseases. The company's lead asset, AL001, in Phase III trials, represents a near-term value driver. Positive clinical trial results for AL001 could lead to regulatory approval and subsequent commercialization, driving revenue growth. The collaboration with GlaxoSmithKline provides financial resources and expertise to support development and commercialization efforts. However, the company's negative profit margin of -680.8% and negative free cash flow of $-0.12 billion highlight the risks associated with clinical-stage biopharmaceutical companies, including the potential for clinical trial failures and regulatory setbacks. Successful development and commercialization of its pipeline assets are crucial for Alector to achieve profitability and generate long-term shareholder value.

Based on FMP financials and quantitative analysis

ALEC Key Highlights

Market capitalization of $251M reflects investor sentiment regarding the company's pipeline and potential.

• Gross margin of 76.4% indicates strong potential profitability upon successful commercialization of its products.
• Phase III clinical trial for AL001 represents a significant milestone and potential near-term catalyst.
• Collaboration with GlaxoSmithKline provides financial resources and validation of Alector's technology.
• Negative P/E ratio of -2.92 reflects the company's current lack of profitability due to ongoing research and development expenses.

Who Are ALEC's Competitors?

ALEC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALEC's Key Strengths?

Novel immuno-neurology approach.

• Advanced clinical-stage pipeline.
• Strategic collaboration with GlaxoSmithKline.
• Experienced management team.

What Are ALEC's Weaknesses?

High cash burn rate.

• Reliance on clinical trial success.
• Limited commercial infrastructure.
• Negative profitability.

What Could Drive ALEC Stock Higher?

Phase III clinical trial results for AL001 in frontotemporal dementia (FTD).

• Initiation of Phase II clinical trials for AL002 in Alzheimer's disease.
• Advancement of AL101 through Phase I clinical trials.
• Expansion of AL001's clinical development into other neurodegenerative diseases.

What Are the Key Risks for ALEC?

Financial-distress signal — its Altman Z-Score of -7.25 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for AL001 or other pipeline assets.
• Regulatory setbacks in obtaining approval for their therapies.
• Competition from other pharmaceutical companies developing therapies for neurodegenerative diseases.
• High cash burn rate and need for additional financing.
• Patent challenges from competitors.

What Are the Growth Opportunities for ALEC?

• Successful completion of the Phase III clinical trial for AL001 in frontotemporal dementia (FTD) represents a significant growth opportunity. The FTD market is underserved, and positive trial results could lead to regulatory approval and commercialization, generating substantial revenue.
• Expansion of AL001's clinical development into other neurodegenerative diseases, such as Alzheimer's and Parkinson's, could broaden its market potential. Positive data in these indications could lead to additional regulatory approvals and revenue streams. The Alzheimer's and Parkinson's disease markets are significantly larger than the FTD market, offering substantial growth potential for Alector.
• Advancement of other pipeline assets, such as AL101, AL002, AL003, and AL044, through clinical development could create additional value. Each of these assets targets different mechanisms or pathways involved in neurodegeneration, providing multiple shots on goal. Successful development of these assets could diversify Alector's revenue streams and reduce its reliance on AL001.
• Strategic collaborations and partnerships with other pharmaceutical companies could provide additional funding and expertise to support Alector's growth. The collaboration with GlaxoSmithKline is a prime example of this strategy. Additional partnerships could accelerate the development and commercialization of Alector's pipeline assets and expand its reach into new markets.
• Expansion into new therapeutic areas within immuno-neurology could provide long-term growth opportunities. Alector's expertise in targeting the brain's immune system could be applied to other neurological disorders beyond neurodegenerative diseases. This could involve developing new therapies for conditions such as multiple sclerosis, stroke, or traumatic brain injury.

What Are ALEC's Competitive Advantages?

• Proprietary immuno-neurology platform.
• Strong intellectual property portfolio protecting their therapies and technologies.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in drug development and commercialization.

What Does ALEC Do?

Founded in 2013 and headquartered in South San Francisco, California, Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases. The company's approach centers on immuno-neurology, targeting the brain's immune system to combat diseases like Alzheimer's, Parkinson's, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). Alector's lead product candidate, AL001, a humanized recombinant monoclonal antibody, is currently in Phase III clinical trials for FTD and is also being explored for Alzheimer's, Parkinson's, and ALS. AL101 is in Phase I clinical trials for neurodegenerative diseases, including Alzheimer's and Parkinson's. Other pipeline assets include AL002, in Phase II for Alzheimer's disease, AL003, in Phase I for Alzheimer's disease, and AL044, targeting MS4A4A, a risk gene for Alzheimer's disease. Alector collaborates with Adimab, LLC for antibody research and development, and has a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, including AL001 and AL101. This partnership aims to accelerate the development and commercialization of these potential treatments for neurodegenerative conditions.

What Products and Services Does ALEC Offer?

• Develop therapies for neurodegenerative diseases.
• Focus on immuno-neurology, targeting the brain's immune system.
• Develop humanized recombinant monoclonal antibodies.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Collaborate with other companies for research and development.
• Seek regulatory approval for their therapies from health authorities.

How Does ALEC Make Money?

• Develop and commercialize therapies for neurodegenerative diseases.
• Generate revenue through sales of approved therapies.
• Collaborate with pharmaceutical companies for development and commercialization, receiving upfront payments, milestone payments, and royalties.
• Out-license their technologies to other companies.

What Industry Does ALEC Operate In?

Alector operates within the biotechnology industry, which is characterized by high risk and high reward. The market for neurodegenerative disease therapies is substantial and growing, driven by an aging population and increasing prevalence of conditions like Alzheimer's and Parkinson's. Competition is intense, with numerous companies pursuing different approaches to treat these diseases. Alector's immuno-neurology approach differentiates it from competitors focusing on other mechanisms, such as amyloid plaques or tau tangles. The success of Alector depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy in its trials.

Who Are ALEC's Key Customers?

• Patients suffering from neurodegenerative diseases, such as Alzheimer's, Parkinson's, and frontotemporal dementia.
• Healthcare providers who prescribe and administer Alector's therapies.
• Pharmaceutical companies who collaborate with Alector on development and commercialization.

Alector, Inc. (ALEC) Valuation Context

Valued at $251M, ALEC is classified as a micro-cap stock. Relative to its peer group, ALEC's quantitative score of 12/100 is below the peer average of 82/100.

ALEC Revenue & Earnings Trend

In Q2 2026, ALEC generated $3.3M in top-line revenue, marking a sequential increase of 217.4%. The company recorded a net loss of $23.0M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ALEC averaged $-0.28 in diluted EPS.

Company Profile

Alector, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Arnon Rosenthal. ALEC has traded publicly since 2019.

Key Financial Metrics

Return on assets is -52.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -72.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -52.5%, the inverse of the P/E and a quick read on earnings relative to price.

Alector, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.25 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Alector, Inc. revenue of about $6.9M for fiscal 2026, with EPS near $-0.89. The estimate reflects 6 contributing analysts.

ALEC Financials

ALEC Latest News

No recent news available for ALEC.

ALEC Analyst Consensus

ALEC MoonshotScore

Alector, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources